Pharmafile Logo
Pharmafocus logo
Advanced Search

CML

Showing 12 posts of 12 posts found.

Iclusig image

EMA keeps Ariad cancer drug on the market

October 13, 2014
Sales and Marketing Ariad, CML, EMA, PRAC, iclusig, leukaemia, ponatinib

The EMA has recommended Ariad’s leukaemia drug Iclusig (ponatinib) should continue to be used under its current indication despite ongoing …

News
Pharmaxis image

PMCPA raps Pharmaxis

June 16, 2014
Manufacturing and Production, Sales and Marketing ABPI, CML, PMCPA, pharmaxis

Pharmaxis Pharmaceuticals has been given the most severe punishment that the PMCPA can hand out following a series of breaches …

News
abbvie image

CLL drug achieves ‘unprecedented’ remissions

December 9, 2013
Research and Development, Sales and Marketing AbbVie, CML, Genentech, abt-199

AbbVie and Genentech’s investigational oncology drug ABT-199 has performed well in a Phase I trial for blood cancer, according to …

News
Pfizer image

NICE rejects Bosulif

November 28, 2013
Sales and Marketing CML, NHS, NICE, Pfizer, bosulif

 In a blow for Pfizer NICE has categorically rejected the manufacturer’s Bosulif as a treatment for previously-treated chronic myeloid leukaemia …

News
iclusig image

Ariad ditches CML trial

October 21, 2013
Research and Development, Sales and Marketing Ariad, CML, iclusig

Ariad Pharmaceuticals has ditched its late-stage trial of Iclusig in patients with newly-diagnosed chronic myeloid leukemia (CML) after blood clots …

News
pfizer image

NICE rejects Pfizer blood cancer drug

July 16, 2013
Sales and Marketing BMS, CML, NICE, Pfizer, bosulif

NICE is not recommending Pfizer’s blood cancer drug Bosulif due to uncertainties over its cost effectiveness and survival benefit. In …

News

CHMP nod for Pfizer CML drug

January 21, 2013
Sales and Marketing CHMP, CML, FDA, Pfizer

Pfizer’s cancer drug bosutinib has been given a positive opinion by the CHMP for patients with chronic myelogenous leukemia (CML). …

News

Private equity firm pays $212m for Cambridge Major Labs

January 16, 2013
Manufacturing and Production American Capital, CML, Cambridge

Private equity firm American Capital has said it will pay $212 million to buy out Cambridge Major Laboratories (CML), a …

News
fda_sign_web

Double approval for Pfizer cancer drugs

September 6, 2012
Sales and Marketing CML, Cancer, Glivec, Pfizer, axitinib, rcc

 Two cancer drugs from Pfizer have been approved, one in Europe for kidney cancer and another in the US for …

News

Ariad files new blood cancer drug with the FDA

July 31, 2012
Research and Development, Sales and Marketing Ariad, CML, EMA, FDA, Glivec, blood cancer

Ariad has filed its investigational blood cancer drug ponatinib with the FDA and hopes for an accelerated review. The US …

News
ariad_slideshow-3

Ariad touts next generation CML treatment

June 29, 2012
Research and Development, Sales and Marketing Ariad, CML, Cancer, Europe, Switzerland

Ariad Pharmaceuticals is to expand into Europe following promising results for an investigational cancer drug. The US biotech firm will …

News

Trial hitch for Pfizer’s leukaemia drug submission plans

December 7, 2010
Research and Development, Sales and Marketing CML, Gleevec, Glivec, Pfizer, bosutinib, chronic myeloid leukaemia

Pfizer is pressing ahead with plans to submit bosutinib for European approval despite the chronic myeloid leukaemia drug missing its …

News
The Gateway to Local Adoption Series

Latest content

Just – Evotec given Gates Foundation grant to increase global biotherapeutics access

January 8, 2026

Johnson & Johnson submits robotic surgical system for De Novo classification

January 8, 2026

EA Pharma announces phase 3 trial for new schizophrenia treatment in Japan

January 7, 2026

Eleva appoints Erich Rajkovic as Chief Business Officer

January 7, 2026

MedPharm announces US FDA inspection of North Carolina manufacturing facility

January 6, 2026